Related Experiment Videos
Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia
Benjamin Arthurs1, Kathy Wunderle2, Maylee Hsu3
1Division of Pulmonary & Critical Care Medicine, Veterans Affairs Portland Health Care System, Oregon Health & Science University, 3710 SW US Veterans Hospital Rd, Portland, OR 97239, United States; Department of Medicine, Veterans Affairs Portland Health Care System, Oregon Health & Science University, 3710 SW US Veterans Hospital Rd, Portland, OR 97239, United States.
Abstract:
We report a case of invasive pulmonary aspergillosis in a patient taking ibrutinib, a Bruton's tyrosine kinase inhibitor used to treat refractory chronic lymphocytic leukemia. We hypothesize that ibrutinib promoted this infection by suppressing innate immune responses against Aspergillus. Clinicians should be aware of potential Aspergillus infections in patients treated with this drug.